Business Context and Reporting Period
This Form 8-K Current Report, dated February 1, 2019, details the Initial Public Offering (IPO) of Inmune Bio, Inc. (Nasdaq: INMB), an emerging growth company incorporated in Nevada. The filing reports the entry into material definitive agreements for the sale of common stock and the subsequent listing of the company's shares on the Nasdaq Capital Market.
Key Financial Metrics
- Shares Sold: 1,020,820 shares of common stock.
- Offering Price: $8.00 per share.
- Gross Proceeds: $8,166,560 (before deducting placement agent fees and offering expenses).
- Placement Agent Commissions: $571,659.20 paid to Univest Securities, LLC, WallachBeth Capital, LLC, and WestPark Capital, Inc.
- Advisory Fee: $30,000 payable to Univest upon closing.
- Insider Participation: Insiders purchased shares with an aggregate purchase price of $416,000.
- Warrants Issued: 40,833 warrants issued to placement agents with an exercise price of $9.60 per share, exercisable for five years commencing six months after the effective date.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change reported is the transition from a private entity to a public company through the completion of its IPO. The company received gross proceeds of approximately $8.17 million, significantly increasing its cash position relative to its pre-IPO state. Additionally, the company incurred immediate liabilities related to placement agent commissions and future obligations for advisory fees and warrant exercises.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing confirms the successful closing of the IPO and the commencement of trading under the ticker symbol "INMB" on February 4, 2019. The company utilized a best efforts basis for the offering.
Risks and Contingencies: The filing notes that the warrants issued to placement agents may be exercised on a cashless basis if no effective registration statement is available for the underlying shares. As an emerging growth company, the registrant has not elected to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the net proceeds after deducting all offering expenses beyond the stated placement agent commissions.
- Review the full text of the Placement Agent Agreement and Warrant terms filed as exhibits to understand dilution risks.
- Confirm the company's cash runway and burn rate in subsequent filings (e.g., 10-K or 10-Q) as this 8-K does not disclose operating expenses or cash reserves.
- Monitor the trading volume and price stability of the "INMB" ticker on the Nasdaq Capital Market post-listing.